Stay updated with breaking news from Trials Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten
Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.
Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.
Jaime R. Merchán, MD, spotlights case studies of patients with rare non-ccRCC histologies, discussing their clinical presentation, recent data on immunotherapy and targeted treatment options for the management of these disease subtypes, and patient outcomes on these therapies.
Jaime R. Merchán, MD, discusses the evolution and current role of IO/TKI regimens in advanced RCC; highlights data from the phase 3 CLEAR and KEYNOTE-426 trials supporting the use of pembrolizumab-based regimens in untreated ccRCC; and speculates on how future biomarker-driven research could improve the benefit seen with these combinations in this disease.